Laurus Labs
- All
- News
-
ChatGPT Was Asked To Choose Between Laurus And Divis Labs. Here's What It Replied.
How ChatGPT refused to compare two pharma stocks and left the decision to us.
-
Fire At Pharma Lab In Andhra Pradesh Kills 4
Indian drugmaker Laurus Labs said on Tuesday that four of its employees died following a flash fire in a room in a manufacturing block of its plant in Visakhapatnam, Andhra Pradesh.
-
4 Killed, 1 Injured In Fire At Pharma Company Lab In Andhra Pradesh
Four workers were killed while one was seriously injured in a flash fire that was reported in Paravada Laurus Pharma labs Limited Company in Andhra Pradesh's Anakapalli, according to an official on late Monday evening.
-
These 5 Companies' Capital Expenditure Plans Are Nearing Completion
Tracking a company's capex plans provides information about its growth prospects and indicates the managements outlook.
-
Laurus Labs Gains On Receiving License To Market Anti-Covid Drug 2DG
Laurus Labs shares have so far this year surged a whopping 95 per cent, outperforming the Sensex which has advanced 10 per cent.
-
Laurus Labs Shares Surge On Credit Rating Upgrade
CARE Ratings upgraded Laurus Labs' Long Term Bank Facilities worth Rs 1,930.64 crore to CARE AA Stable from CARE AA-.
-
Laurus Labs Gains Over 2% On Richcore Lifesciences Acquisition
Laurus Labs acquired a 72.55 per cent stake in biotech company, Richcore Lifesciences from Eight Roads Ventures and VenturEast for Rs 246.67 crore.
-
Stocks To Watch In Trade Today: Lakshmi Vilas Bank, Laurus Labs
Lakshmi Vilas Bank shares will be in focus after the government, on Wednesday, approved the merger of Lakshmi Vilas Bank with DBS Bank India
-
This Company Is Ready To Flood The US With Cheap HIV Drugs
Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the US market with the low-cost copycat medicines.
-
Laurus Labs Makes Strong Market Debut, Shares Jump 16%
Laurus Labs makes active pharmaceutical ingredients or APIs that go into the making a range of medicines, chiefly HIV/AIDS drugs.
-
Laurus Labs IPO Fully Subscribed
Laurus Labs was selling up to Rs 300 crore in new shares and some its shareholders were selling about 24.1 million shares in a price range of Rs 426 to Rs 428 per share.
-
Laurus Labs IPO: Five Things To Know Before Investing
Hyderabad-based pharma company Laurus Labs launched its initial public offer (IPO) on Tuesday to raise Rs 1,330 crore from the primary markets.
-
Laurus Labs Garners Rs 395 Crore From Anchor Investors
The anchor investors included Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.
-
Laurus Labs' Rs 1,332 Crore IPO To Hit Market This Week
The IPO is scheduled to open on December 6 and close on December 8.
-
Laurus Labs Gets Sebi Nod For IPO
Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.
-
ChatGPT Was Asked To Choose Between Laurus And Divis Labs. Here's What It Replied.
How ChatGPT refused to compare two pharma stocks and left the decision to us.
-
Fire At Pharma Lab In Andhra Pradesh Kills 4
Indian drugmaker Laurus Labs said on Tuesday that four of its employees died following a flash fire in a room in a manufacturing block of its plant in Visakhapatnam, Andhra Pradesh.
-
4 Killed, 1 Injured In Fire At Pharma Company Lab In Andhra Pradesh
Four workers were killed while one was seriously injured in a flash fire that was reported in Paravada Laurus Pharma labs Limited Company in Andhra Pradesh's Anakapalli, according to an official on late Monday evening.
-
These 5 Companies' Capital Expenditure Plans Are Nearing Completion
Tracking a company's capex plans provides information about its growth prospects and indicates the managements outlook.
-
Laurus Labs Gains On Receiving License To Market Anti-Covid Drug 2DG
Laurus Labs shares have so far this year surged a whopping 95 per cent, outperforming the Sensex which has advanced 10 per cent.
-
Laurus Labs Shares Surge On Credit Rating Upgrade
CARE Ratings upgraded Laurus Labs' Long Term Bank Facilities worth Rs 1,930.64 crore to CARE AA Stable from CARE AA-.
-
Laurus Labs Gains Over 2% On Richcore Lifesciences Acquisition
Laurus Labs acquired a 72.55 per cent stake in biotech company, Richcore Lifesciences from Eight Roads Ventures and VenturEast for Rs 246.67 crore.
-
Stocks To Watch In Trade Today: Lakshmi Vilas Bank, Laurus Labs
Lakshmi Vilas Bank shares will be in focus after the government, on Wednesday, approved the merger of Lakshmi Vilas Bank with DBS Bank India
-
This Company Is Ready To Flood The US With Cheap HIV Drugs
Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the US market with the low-cost copycat medicines.
-
Laurus Labs Makes Strong Market Debut, Shares Jump 16%
Laurus Labs makes active pharmaceutical ingredients or APIs that go into the making a range of medicines, chiefly HIV/AIDS drugs.
-
Laurus Labs IPO Fully Subscribed
Laurus Labs was selling up to Rs 300 crore in new shares and some its shareholders were selling about 24.1 million shares in a price range of Rs 426 to Rs 428 per share.
-
Laurus Labs IPO: Five Things To Know Before Investing
Hyderabad-based pharma company Laurus Labs launched its initial public offer (IPO) on Tuesday to raise Rs 1,330 crore from the primary markets.
-
Laurus Labs Garners Rs 395 Crore From Anchor Investors
The anchor investors included Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.
-
Laurus Labs' Rs 1,332 Crore IPO To Hit Market This Week
The IPO is scheduled to open on December 6 and close on December 8.
-
Laurus Labs Gets Sebi Nod For IPO
Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.
